Select country change
Shopping cart (0 , 0,00 ) Menu Search
Manufactured by BioVendor

TRAP 5 Human Assay

  • Regulatory status:RUO
  • Type:Immunocapture enzyme activity assay
  • Other names:TRACP 5, Tartrate Resistant Acid Phosphatase 5
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price

Availability on Request RD197025000 96 wells (1 kit)
PubMed Product Details
Technical Data


Immunocapture enzyme activity assay


Serum, Plasma-EDTA

Sample Requirements

25 µl/well


At ambient temperature. Upon receipt, store the product at the temperature recommended below.


Store the kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

0.2–4 U/l

Limit of Detection

0.01 U/l

Intra-assay (Within-Run)

n = 8; CV = 1.6%

Inter-assay (Run-to-Run)

n = 4; CV = 7.0%

Spiking Recovery


Dilution Linearity



  • bovine Non-detectable
  • cat Non-detectable
  • goat Non-detectable
  • hamster Non-detectable
  • horse Non-detectable
  • dog Yes
  • mouse Non-detectable
  • pig Non-detectable
  • rat Non-detectable
  • sheep Non-detectable
  • chicken Not tested
  • monkey Yes
  • rabbit Yes
  • human Yes


  • European Union: for in vitro diagnostic use
  • Rest of the world: for research use only!
  • The total assay time is less than 4 hours
  • The kit measures TRAP 5 proteins exhibiting enzyme activity in serum and EDTA plasma
  • Assay format is 96 wells
  • Quality Controls are recombinant TRAP 5 protein based. No animal sera are used
  • Calibrators are recombinant protein based
  • Components of the kit are provided ready to use, concentrated or lyophilized

Research topic

Bone and cartilage metabolism


TRAP 5 (serum band 5 tartrate-resistant acid phosphatase, TRACP 5; EC is a glycoprotein of 35–37 kDa. TRAP 5 belongs to the most abundant enzymes in osteoclasts. It is expressed in certain differentiated cells of the mononuclear phagocyte system, particularly osteoclasts and alveolar macrophages, where it takes an active part in bone resorption process. High blood levels of TRAP 5 are usually associated with active bone remodelling. Increased serum levels are observed during normal bone growth among healthy children. Elevated serum TRAP levels have been detected in diseases characterized by increased bone resorption; Paget’s disease of the bone, hemodialysis, primary hyperparathyro­idism, metastatic malignancies involving bone resorption, multiple myeloma and bilaterally ovariectomized women. Post-menopausal women have higher levels of serum than post-menopausal women on estrogen replacement therapy. Therefore specific determination of TRAP 5 activity can be essential for clinical assessment of bone metabolism.

Product References (4)


  • Halleen JM, Tiitinen SL, Ylipahkala H, Fagerlund KM, Väänänen HK.Tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of bone resorption.Clin Lab. 2006;52(9-10):499-509. Review. PubMed PMID: 17078477. See more on PubMed
  • Karakaş NM, Tulgar Kınık S, Özdemir B, Muratoğlu Şahin N, Tekindal MA, HaberalA. Congenital Hypothyroidism and Bone Remodeling Cycle. J Clin Res PediatrEndocrinol. 2017 Jun 1;9(2):106-110. doi: 10.4274/jcrpe.3532. Epub 2016 Nov 9.PubMed PMID: 27840329; PubMed Central PMCID: PMC5463281. See more on PubMed
  • Monier-Faugere MC, Mawad H, Malluche HH. Opposite effects of calcitriol andparicalcitol on the parathyroid hormone-(1-84)/large carboxy-terminal-parathyroidhormone fragments ratio in patients with stage 5 chronic kidney disease. Clin JAm Soc Nephrol. 2007 Nov;2(6):1255-60. Epub 2007 Oct 17. PubMed PMID: 17942766. See more on PubMed
  • Taylan A, Sari I, Akinci B, Bilge S, Kozaci D, Akar S, Colak A, Yalcin H,Gunay N, Akkoc N. Biomarkers and cytokines of bone turnover: extensive evaluationin a cohort of patients with ankylosing spondylitis. BMC Musculoskelet Disord.2012 Oct 2;13:191. doi: 10.1186/1471-2474-13-191. PubMed PMID: 23025387; PubMedCentral PMCID: PMC3492209. See more on PubMed
Summary References (9)

References to TRAP 5

  • Minkin C. Bone acid phosphatase: tartrate-resistant acid phosphatase as a marker of osteoclast function. Calcif Tissue Int. 1982, 34, 285–290.
  • Lau KH, Onishi T, Wergedal JE, Singer FR, Baylink DJ. Characterization and assay of tartrate-resistant acid phosphatase activity in serum: potential use to assess bone resorption. Clin Chem. 1987, 33, 458–462.
  • Nakanishi M, Yoh K, Uchida K, Maruo S, Matsuoka A. Improved method for measuring tartrate-resistant acid phosphatase activity in serum. Clin Chem. 1998, 44, 221–225.
  • Halleen JM, Alatalo SL, Suominen H, Cheng S, Janckila AJ, Vaananen HK. Tartrateresistant acid phosphatase 5b: a novel serum marker of bone resorption. J Bone Miner Res. 2000, 15, 133–1345.
  • Lamp EC, Drexler HG. Biology of tartrate-resistant acid phosphatase. Leuk Lymphoma. 2000, 39, 477–484.
  • Nakanishi M, Yoh K, Miura T, Ohasi T, Rai SK, Uchida K. Development of a kinetic assay for band 5b tartrate-resistant acid phosphatase activity in serum. Clin Chem. 2000, 46, 469–473.
  • Waguespack SG, Hui SL, White KE, Buckwalter KA, Econs MJ. Measurement of tartrate-resistant acid phosphatase and the brain isoenzyme of creatine kinase accurately diagnose type II autosomal dominant osteopetrosis but does not identify gene carriers. J Clin Endocrinol Metab. 2002, 87, 2212–2217.
  • Igarashi Y, Lee M, Matsuzaki S. Acid phosphatases as markers of bone metabolism. J Chromatogr B. 2002, 781, 345–358.
  • Terpos E, de la Fuente J, Szydlo R, Hatjiharissi E, Viniou N, Meletis J, Yataganas X, Goldman JM, Rahemtulla A. Tartrate-resistant acid phosphatase isoform 5b: a novel serum markerfor monitoring bone disease in multiple myeloma. Int J Cancer. 2003, 106, 455–457.
Related Products Docs